المؤلفون: V. Syutkin E., V. Gorodetskiy R., A. Salienko A., N. Probatova A., N. Kupryshina A., M. Novruzbekov S., В. Сюткин Е., В. Городецкий Р., А. Салиенко А., Н. Пробатова А., Н. Купрышина А., М. Новрузбеков С.

المصدر: Transplantologiya. The Russian Journal of Transplantation; Том 13, № 3 (2021); 272-279 ; Трансплантология; Том 13, № 3 (2021); 272-279 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2021-13-3

مصطلحات موضوعية: liver transplantation, post-transplant lymphoproliferative diseases, proliferation signal inhibitors, everolimus, трансплантация печени, посттрансплантационные лимфопролиферативные заболевания, ингибиторы пролиферативного сигнала, эверолимус

وصف الملف: application/pdf

العلاقة: https://www.jtransplantologiya.ru/jour/article/view/587/638Test; https://www.jtransplantologiya.ru/jour/article/view/587/644Test; Doak PB, Montgomerie JZ, North JD, Smith F. Reticulum cell sarcoma after renal homotransplantation and azathioprine and prednisone therapy. Br Med J. 1968;4(5633):746–748. PMID: 4881420 https://doi.org/10.1136/bmj.4.5633.746Test; Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1(8377):583–587. PMID: 6142304 https://doi.org/10.1016/s0140-6736Test(84)90994-2; Swerdlow S. Post-transplant lymphoproliferative disorders. In: WHO classification of tumours of haematopoietic and lymphoid tissues. 4 th ed. Lyon: International Agency for Research on Cancer; 2017. p. 453–462.; Taylor AL, Marcus R, Bradley JA. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol. 2005;56(1):155–167. PMID: 15979320 https://doi.org/10.1016/j.critrevonc.2005.03.015Test; Soutar R, Lucraft H, Jackson G, Reece A, Bird J, Low E, et al. Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. Br J Haematol. 2004;124(6):717–726. PMID: 15009059 https://doi.org/10.1111/j.1365-2141.2004.04834.xTest; Kilciksiz S, Karakoyun-Celik O, Agaoglu FY, Haydaroglu A. A review for solitary plasmacytoma of bone and extramedullary plasmacytoma. Sci World J. 2012;2012:895765. PMID: 22654647 https://doi.org/10.1100/2012/895765Test; Trappe R, Zimmermann H, Fink S, Reinke P, Dreyling M, Pascher A, et al. Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell posttransplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica. 2011;96(7):1067–1071. PMID: 21719885 https://doi.org/10.3324/haematol.2010.039214Test; Richendollar BG, Hsi ED, Cook JR. Extramedullary plasmacytoma-like posttransplantation lymphoproliferative disorders: clinical and pathologic features. Am J Clin Pathol. 2009;132(4):581– 588. PMID: 19762536 https://doi.org/10.1309/AJCPX70TIHETNBRLTest; Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–183. PMID: 23737188 https://doi.org/10.1007/s11899-013-0162-5Test; El-Salem M, Raghunath PN, Marzec M, Wlodarski P, Tsai D, Hsi E, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest. 2007;87(1):29–39. PMID: 17075574 https://doi.org/10.1038/labinvest.3700494Test; Nepomuceno RR, Balatoni CE, Natkunam Y, Snow AL, Krams SM, Martinez OM. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res. 2003;63(15):4472–4480. PMID: 12907620; Majewski M, Korecka M, Kossev P, Li S, Goldman J, Moore J, et al. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA. 2000;97(8): 4285–4290. PMID: 10759564 https://doi.org/10.1073/pnas.080068597Test; Majewski M, Korecka M, Joergensen J, Fields L, Kossev P, Schuler W, et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation. 2003;75(10):1710–1717. PMID: 12777861 https://doi.org/10.1097/01.TP.0000063934.89714.19Test; Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus- induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47(5):e67–72. PMID: 16632009 https://doi.org/10.1053/j.ajkd.2006.01.029Test; Boratynska M, Smolska D. Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int. 2008;21(6):605– 608. PMID: 18282244 https://doi.org/10.1111/j.1432-2277.2008.00655.xTest; Pascual J. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(Suppl 1): i27–35. PMID: 17456616 https://doi.org/10.1093/ndt/gfm088Test; Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T. Remission of Epstein-Barr virus-positive post-transplant lymphoproliferative disorder by conversion to everolimus in a kidney transplant recipient. Transpl Infect Dis. 2019;21(4):e13116. PMID: 31102475 https://doi.org/10.1111/tid.13116Test; Li J, Liu Z, Li Y, Jing Q, Wang H, Liu H, et al. Everolimus shows synergistic antimyeloma effects with bortezomib via the AKT/mTOR pathway. J Investig Med. 2019;67(1):39–47. PMID: 29997148 https://doi.org/10.1136/jim-2018-000780Test; Günther A, Baumann P, Burger R, Kellner C, Klapper W, Schmidmaier R, et al. Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. Haematologica. 2015;100(4):541–547. PMID: 25682600 https://doi.org/10.3324/haematol.2014.116269Test; Brennan DC, Aguado JM, Potena L, Jardine AG, Legendre C, Säemann MD, et al. Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms. Rev Med Virol. 2013;23(2):97–125. PMID: 23165654 https://doi.org/10.1002/rmv.1733Test; Pascual J, Royuela A, Fernández AM, Herrero I, Delgado JF, Solé A, et al. Role of mTOR inhibitors for the control of viral infection in solid organ transplant recipients. Transpl Infect Dis. 2016;18(6):819–831. PMID: 27600985 https://doi.org/10.1111/tid.12601Test; https://www.jtransplantologiya.ru/jour/article/view/587Test

الإتاحة: https://doi.org/10.23873/2074-0506-2021-13-3-272-279Test
https://doi.org/10.23873/2074-0506-2021-13-3Test
https://doi.org/10.1136/bmj.4.5633.746Test
https://doi.org/10.1016/s0140-6736Test(84)90994-2
https://doi.org/10.1016/j.critrevonc.2005.03.015Test
https://doi.org/10.1111/j.1365-2141.2004.04834.xTest
https://doi.org/10.1100/2012/895765Test
https://doi.org/10.3324/haematol.2010.039214Test
https://doi.org/10.1309/AJCPX70TIHETNBRLTest
https://doi.org/10.1007/s11899-013-0162-5Test

المؤلفون: V. Syutkin E., A. Salienko A., O. Olisov D., S. Zhuravel V., M. Novruzbekov S., В. Сюткин Е., А. Салиенко А., О. Олисов Д., С. Журавель В., М. Новрузбеков С.

المصدر: Transplantologiya. The Russian Journal of Transplantation; Том 13, № 2 (2021); 121-129 ; Трансплантология; Том 13, № 2 (2021); 121-129 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2021-13-2

مصطلحات موضوعية: liver transplantation, immunosuppression, calcineurin inhibitors, proliferative signal inhibitors, everolimus, трансплантация печени, иммуносупрессия, ингибиторы кальциневрина, ингибиторы пролиферативного сигнала, эверолимус

وصف الملف: application/pdf

العلاقة: https://www.jtransplantologiya.ru/jour/article/view/569/619Test; https://www.jtransplantologiya.ru/jour/article/view/569/629Test; Karie-Guigues S, Janus N, Saliba F, Dumortier J, Duvoux C, Calmus Y, et al. Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study. Liver Transpl. 2009;15(9):1083–1091. https://doi.org/10.1002/lt.21803Test; Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am J Transplant. 2013;13(7):1734-1745. https://doi.org/10.1111/ajt.12280Test; Fischer L, Saliba F, Kaiser GM, De Carlis L, Metselaar HJ, De Simone P, et al. Three-year outcomes in de novo liver transplant patients receiving everolimus with reduced tacrolimus: Follow-up results from a randomized, multicenter study. Transplantation. 2015;99(7):1455-1462. https://doi.org/10.1097/TP.0000000000000555Test; Lucey MR, Terrault N, Ojo L, Hay J, Neuberger J, Blumberg E, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013;19(1):3–26. https://doi.org/10.1002/lt.23566Test; Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41. https://doi.org/10.1159/000180580Test; Bilbao I, Salcedo M, Gómez MA, Jimenez C, Castroagud í n J, Fabregat J, et al. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain. Liver Transpl. 2015;21(8):1056–1065. https://doi.org/10.1002/lt.24172Test; Lopez FN, Alfocea PA, Ortega Suazo EJ, López Garrido MA, Massare BA, Gila Medina AM, et al. Impact of everolimus-based immunosuppression on renal function in liver transplant recipients. Transplant Proc. 2020;52(2):556–558. PMID: 32035673 https://doi.org/10.1016/j.transproceed.2019.12.012Test; Cholongitas E, Goulis I, Theocharidou E, Antoniadis N, Fouzas I, Giakoustidis D, et al. Everolimus-based immunosuppression in liver transplant recipients: a single-centre experience. Hepatol Int. 2014;8(1):137–145. PMID: 26202415 https://doi.org/10.1007/s12072-013-9492-6Test; https://www.jtransplantologiya.ru/jour/article/view/569Test

الإتاحة: https://doi.org/10.23873/2074-0506-2021-13-2-121-129Test
https://doi.org/10.23873/2074-0506-2021-13-2Test
https://doi.org/10.1002/lt.21803Test
https://doi.org/10.1111/ajt.12280Test
https://doi.org/10.1097/TP.0000000000000555Test
https://doi.org/10.1002/lt.23566Test
https://doi.org/10.1159/000180580Test
https://doi.org/10.1002/lt.24172Test
https://doi.org/10.1016/j.transproceed.2019.12.012Test
https://doi.org/10.1007/s12072-013-9492-6Test

المؤلفون: V. Syutkin E., O. Andreytseva I., V. Nikulina P., A. Chugunov O., В. Сюткин Е., О. Андрейцева И., В. Никулина П., А. Чугунов О.

المصدر: Transplantologiya. The Russian Journal of Transplantation; № 1-2 (2012); 10-14 ; Трансплантология; № 1-2 (2012); 10-14 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2012-0-1-2

مصطلحات موضوعية: everolimus, liver transplantation, calcineurin inhibitors, renal failure, эверолимус, трансплантация печени, ингибиторы кальциневрина, почечная недостаточность

وصف الملف: application/pdf

العلاقة: https://www.jtransplantologiya.ru/jour/article/view/373/434Test; Efficacy, tolerance, and safety of mammalian target of rapamycin inhibitors as rescue immunosuppressants in liver transplantation / J.M. Alamo [et al.] // Transplant. Proc. – 2009. – 41(6). – P. 2181–2183.; Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction / J.F. Castroagudin [et al.] // Liver Transplant. – 2009. – 15 (12). – P. 1792–1797.; Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancie / C. Chiurchiu [et al.] // Transplant. Proc. – 2010. – 42 (1). – P. 277–279.; Conversion to everolimus monotherapy in maintenance liver transplantation. feasibility, safety, and impact on renal function / P. De Simone [et al.] // Transplant. Int. – 2009. – 22 (3). – P. 279–286.; Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms / J. GomezCamarero [et al.] // Transplant. – 2007. – 84 (6). – P. 786–791.; Long-term renal function in liver transplant recipients and impact of immunosuppressive regimens (calcineurin inhibitors alone or in combination with mycophenolate mofetil): the TRY study / S. Karie-Guigues [et al.] // Liver Transplant. – 2009. – 15 (9). – P. 1083–1091.; Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results / G. Levy [et al.] // Liver Transplant. – 2006. – 12 (11) – P. 1640–1648.; Rescue immunosuppression with mammalian target of rapamycin inhibitor drugs in liver transplantation / J.M. Martinez [et al.] // Transplant. Proc. – 2010. – 42 (2). – P. 641–643.; Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function / M. Masetti [et al.] // Am. J. Transplant. – 2010. – 10 (10). – P. 2252–2262.; Chronic renal failure after transplantation of a nonrenal orga / A.O. Ojo [et al.] // N. Engl. J. Med. – 2003. – 349 (10). – P. 931–940.; Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis / F. Saliba [et al.] // Liver Transplant. – 2011. – 17 (8). – P. 905–913.; https://www.jtransplantologiya.ru/jour/article/view/373Test

الإتاحة: https://doi.org/10.23873/2074-0506-2012-0-1-2-10-14Test
https://doi.org/10.23873/2074-0506-2012-0-1-2Test
https://www.jtransplantologiya.ru/jour/article/view/373Test

المؤلفون: B. Yaremin I., E. Parabina V., U. Maslikova V., V. Aleksandrova E., Б. Яремин И., Е. Парабина В., У. Масликова В., В. Александрова Э.

المصدر: Transplantologiya. The Russian Journal of Transplantation; Том 9, № 4 (2017); 312-316 ; Трансплантология; Том 9, № 4 (2017); 312-316 ; 2542-0909 ; 2074-0506 ; 10.23873/2074-0506-2017-9-4

مصطلحات موضوعية: rhabdomyolysis in transplantation, pregnancy after kidney transplantation, pregnancy and immunosuppression, kidney transplantation, everolimus, рабдомиолиз в трансплантации, беременность после трансплантации почки, беременность и иммуносупрессия, трансплантация почки, эверолимус

وصف الملف: application/pdf

العلاقة: https://www.jtransplantologiya.ru/jour/article/view/198/246Test; Кандидова И.Е. Беременность у реципиенток почечного аллотрансплантата: дис. … канд. мед. наук. М., 2002. 130 с.; Андриевская Т.Г., Кутузова Р.И., Карпова В.В. Случай острой почечной недостаточности в результате рабдомиолиза. Сибирский медицинский журнал (Иркутск). 2011;(1):170–172.; Есназарова Г.С., Омарова Х.С., Шамшидинова М.А., Ордаханова М.С., Байжигитова Н.Б. Клинический случай рабдомиолиза. Медицина (Алматы). 2016;2(164):55–57.; Кулаков В.И., Мурашко Л.Е., Мойсюк Я.Г. и др. Беременность и роды у женщин с пересаженной почкой. Акушерство и гинекология. 2004;(2):27–32.; Миронов Л.Л. Рабдомиолиз. Медицина неотложных состояний. 2006;6(7):7–14.; Прокопенко Е.И., Никольская И.Г. Беременность у пациенток с трансплантированной почкой. Альманах клинической медицины. 2014;30:99–107. DOI:10.18786/2072-0505-2014-30-99-107; Мурашко Л.Е., Кандидова И.Е., Сухих Г.Т. Заболевания почек у беременных и беременность после трансплантации почки. М., 2012. 202 с.; Armenti V.T., Moritz M.J., Cardonick E.H., Davison J.M. Immunosuppression in pregnancy: choices for infant and maternal health. Drugs. 2002;62(16):2361–2375. PMID:12396228; Chittka D., Hutchinson J.A. Pregnancy After Renal Transplantation. Transplantation. 2017; 101(4): 675–678. DOI:10.1097/TP.0000000000001649; Brosens I., Pijnenborg R., Benagiano G. Risk of obstetrical complications in organ transplant recipient pregnancies. Transplantation. 2013;96(3):227–233. DOI:10.1097/TP.0b013e318289216e; Fiocchi R., D’Elia E., Vittori C., et al. First Report of a Successful Pregnancy in an Everolimus-Treated HeartTransplanted Patient: Neonatal Disappearance of Immunosuppressive Drugs. Am. J. Transplant. 2016;16(4):1319–1322. DOI:10.1111/ajt.13514; Framarino dei Malatesta M, Corona LE, De Luca L, et al. Successful pregnancy in a living-related kidney transplant recipient who received sirolimus throughout the whole gestation. Transplantation. 2011;91(9):e69–e71. DOI:10.1097/TP.0b013e3182154267; https://www.jtransplantologiya.ru/jour/article/view/198Test

الإتاحة: https://doi.org/10.23873/2074-0506-2017-9-4-312-316Test
https://doi.org/10.23873/2074-0506-2017-9-4Test
https://doi.org/10.18786/2072-0505-2014-30-99-107Test
https://doi.org/10.1097/TP.0000000000001649Test
https://doi.org/10.1097/TP.0b013e318289216eTest
https://doi.org/10.1111/ajt.13514Test
https://doi.org/10.1097/TP.0b013e3182154267Test
https://www.jtransplantologiya.ru/jour/article/view/198Test